Peptide · Fact sheet
Pemvidutide
Also known as ALT-801
Pemvidutide is not FDA approved. Phase 2 studies report reductions in liver fat, MASH activity, and body weight, but confirmatory evidence, fibrosis benefit, long-term safety, and major clinical outcomes remain unresolved.
What is Pemvidutide?
Pemvidutide is a manufactured peptide designed to activate GLP-1 and glucagon receptors.
It is being developed primarily for metabolic liver disease and obesity, with trial endpoints spanning imaging, biopsy, biomarkers, and weight.
Benefits & claims
Its glucagon activity is intended to add liver-fat and energy-expenditure effects to GLP-1 biology.
Positive mid-stage results are scientifically meaningful but remain less mature than a successful confirmatory program or regulatory approval.
What the evidence supports
- A randomized MASLD study reported lower liver fat and body weight than placebo.
- The IMPACT Phase 2b study reported MASH-resolution signals, while a clear confirmatory fibrosis benefit remains a central question.
Research areas
- MASH and MASLD
- Liver fat
- Obesity
- Fibrosis and cardiometabolic markers
- MASH with fibrosis
- Chronic weight management
- Metabolic liver disease
Dosage & frequency
Human study contextPemvidutide remains investigational for metabolic and liver disease. A trial schedule is not an approved obesity or MASH prescription.
Randomized MASLD trial
Patients with BMI at least 28 and liver fat content at least 10%
- Amount
- 1.2, 1.8 or 2.4 mg in separate study groups
- Frequency
- Once weekly for twelve weeks
- Route studied or labeled
- Subcutaneous
Liver-fat study, not an approved MASH or obesity regimen.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- This dual GLP-1/glucagon agonist is distinct from semaglutide or tirzepatide.
Interactions & precautions
- Investigational GLP-1/glucagon trial regimens do not establish compatibility with other incretin medicines or arbitrary combinations.
What is still unresolved
- Final indication, maintenance regimen, and long-term clinical-outcome evidence remain unresolved.
Side effects & risks
- Gastrointestinal adverse effects are common across this drug class and appeared in pemvidutide trials.
- Trial discontinuations and sponsor-selected analyses can affect apparent efficacy.
- Uncommon and long-term harms are not yet characterized as they are for approved medicines.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Early human evidenceRandomized Phase 2 studies support biological and clinical signals, including liver-fat and biopsy outcomes. Larger confirmatory trials and longer safety follow-up are still needed.
Studies
Controlled trial of liver-fat, inflammatory, and body-weight outcomes.
Biopsy-based MASH and fibrosis study with short primary follow-up.
Official Phase 2b trial design, status, population, and endpoints.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Pemvidutide remains investigational in the United States. Its MASH and obesity programs have not produced an FDA-approved product.
Mid-stage MASH and metabolic research
Pemvidutide has Phase 2 evidence and a completed Phase 2b MASH program, but confirmatory development and regulatory review remain unresolved.
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Whether MASH improvements are confirmed in Phase 3
- Whether fibrosis and liver-related clinical outcomes improve
- Long-term cardiovascular and safety outcomes
- How its benefit-risk profile compares directly with other incretin and glucagon co-agonists
Summary
Pemvidutide remains investigational. Phase 2 liver and weight findings need confirmatory and longer-term clinical evidence.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedRandomized pemvidutide MASLD study
Controlled trial of liver-fat, inflammatory, and body-weight outcomes.
- clinical trialsClinicalTrials.gov: IMPACT
Official Phase 2b trial design, status, population, and endpoints.